Korneeva Vera A, Trubetskov Mikhail M, Korshunova Alena V, Lushchekina Sofya V, Kolyadko Vladimir N, Sergienko Olga V, Lunin Vladimir G, Panteleev Mikhail A, Ataullakhanov Fazoil I
From the Laboratory of the Molecular Mechanisms of Hemostasis, Center for Theoretical Problems of Physicochemical Pharmacology of Russian Academy of Sciences, Moscow 119991, Russia.
From the Laboratory of the Molecular Mechanisms of Hemostasis, Center for Theoretical Problems of Physicochemical Pharmacology of Russian Academy of Sciences, Moscow 119991, Russia, the Department of Physics, Moscow State University, Moscow 119992, Russia.
J Biol Chem. 2014 May 16;289(20):14109-20. doi: 10.1074/jbc.M114.553735. Epub 2014 Apr 4.
Activated factor XII (FXIIa) is selectively inhibited by corn Hageman factor inhibitor (CHFI) among other plasma proteases. CHFI is considered a canonical serine protease inhibitor that interacts with FXIIa through its protease-binding loop. Here we examined whether the protease-binding loop alone is sufficient for the selective inhibition of serine proteases or whether other regions of a canonical inhibitor are involved. Six CHFI mutants lacking different N- and C-terminal portions were generated. CHFI-234, which lacks the first and fifth disulfide bonds and 11 and 19 amino acid residues at the N and C termini, respectively, exhibited no significant changes in FXIIa inhibition (Ki = 3.2 ± 0.4 nm). CHFI-123, which lacks 34 amino acid residues at the C terminus and the fourth and fifth disulfide bridges, inhibited FXIIa with a Ki of 116 ± 16 nm. To exclude interactions outside the FXIIa active site, a synthetic cyclic peptide was tested. The peptide contained residues 20-45 (Protein Data Bank code 1BEA), and a C29D substitution was included to avoid unwanted disulfide bond formation between unpaired cysteines. Surprisingly, the isolated protease-binding loop failed to inhibit FXIIa but retained partial inhibition of trypsin (Ki = 11.7 ± 1.2 μm) and activated factor XI (Ki = 94 ± 11 μm). Full-length CHFI inhibited trypsin with a Ki of 1.3 ± 0.2 nm and activated factor XI with a Ki of 5.4 ± 0.2 μm. Our results suggest that the protease-binding loop is not sufficient for the interaction between FXIIa and CHFI; other regions of the inhibitor also contribute to specific inhibition.
在其他血浆蛋白酶中,活化的因子 XII(FXIIa)可被玉米哈格曼因子抑制剂(CHFI)选择性抑制。CHFI 被认为是一种典型的丝氨酸蛋白酶抑制剂,它通过其蛋白酶结合环与 FXIIa 相互作用。在此,我们研究了单独的蛋白酶结合环是否足以选择性抑制丝氨酸蛋白酶,或者典型抑制剂的其他区域是否也参与其中。我们构建了六个缺失不同 N 端和 C 端部分的 CHFI 突变体。CHFI - 234 分别缺失第一个和第五个二硫键以及 N 端和 C 端的 11 个和 19 个氨基酸残基,其对 FXIIa 的抑制作用(Ki = 3.2 ± 0.4 nM)无显著变化。CHFI - 123 缺失 C 端的 34 个氨基酸残基以及第四个和第五个二硫键,其对 FXIIa 的抑制 Ki 值为 116 ± 16 nM。为了排除 FXIIa 活性位点之外的相互作用,我们测试了一种合成环肽。该肽包含 20 - 45 位残基(蛋白质数据库代码 1BEA),并包含 C29D 替换以避免未配对半胱氨酸之间形成不必要的二硫键。令人惊讶的是,分离出的蛋白酶结合环未能抑制 FXIIa,但保留了对胰蛋白酶(Ki = 11.7 ± 1.2 μM)和活化因子 XI(Ki = 94 ± 11 μM)的部分抑制作用。全长 CHFI 对胰蛋白酶的抑制 Ki 值为 1.3 ± 0.2 nM,对活化因子 XI 的抑制 Ki 值为 5.4 ± 0.2 μM。我们的结果表明,蛋白酶结合环不足以介导 FXIIa 与 CHFI 之间的相互作用;抑制剂的其他区域也有助于特异性抑制。